What Starling Medical does

Starling Medical is a Houston-based, venture-backed medical device company developing an at-home urine analysis platform for early identification of chronic urinary conditions, principally recurrent urinary tract infections (rUTIs). Its flagship product, UrinDx, is a toilet-mounted mini-spectrophotometer device that passively captures spectral data from every bathroom visit, transmits nightly readings via Bluetooth 5.1 to a smartphone app, and routes them to Starling's proprietary StarStream cloud dashboard, where nurse-monitored algorithms triage patients pre-symptomatically and escalate confirmed clinical concerns to prescribing urology, primary care, and OBGYN practices. A second product, Pete, extends the same hardware concept to the general-wellness market as a direct-to-consumer device for hydration and urine-clarity tracking, with no prescription required and HSA/FSA payment accepted ahead of a planned 2026 ship date.

The company operates two parallel go-to-market motions. UrinDx follows a B2B2C, insurance-reimbursed remote patient monitoring model: providers enroll patients who meet the AUA 2022 rUTI definition, Starling ships devices directly to patients' homes, and Starling invoices the prescribing practice at a flat monthly rate per patient while the practice seeks reimbursement for triage and monitoring services — leaving most patients with a $0 copay. Pete follows a pure direct-to-consumer e-commerce model via Starling's own storefront, with $1 reservations converting to a 20% launch discount and Stripe-handled payments including HSA/FSA cards. Both products integrate with Apple HealthKit as a third-party data source, and the platform is HIPAA-aware in its handling of protected health information.

Starling is currently pre-FDA-clearance for UrinDx and pre-shipping for Pete, with a 1–10 person team based primarily in Houston, Texas (plus an Austin-adjacent presence indicated by job listings). The company was accepted into Y Combinator in June 2022, closed a $3.4 million seed round led by Rebel Fund in January 2023 with a broad investor syndicate, added Wellstar CATALYST as a strategic healthcare-system backer in October 2024, and filed an SEC Form D exempt offering for up to $1.75 million in early 2026 to bridge through regulatory clearance and consumer manufacturing scale-up.

Name

Starling Medical

Legal name

Starling Medical, Inc.

Website

https://starlingmedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Starling Medical is a Houston-based medical device company building a toilet-mounted urine analysis platform — UrinDx for prescribed recurrent UTI monitoring and Pete for direct-to-consumer wellness — paired with a nurse-monitored AI dashboard for pre-symptomatic clinical triage.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring Devices

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine) (HLAHAOAE)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Hospital-at-Home & Virtual Ward IoT (HLACAPAC), Urinalysis & Routine Screening Diagnostics (HLAHAAAG), Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)

Keywords

• At-home urine monitoring
• Remote patient monitoring
• Urinary health diagnostics
• Spectrophotometry devices
• Chronic UTI prevention

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. UrinDx – Insurance-Reimbursed Remote Patient Monitoring: UrinDx is provided to patients at no charge; Starling Medical invoices the participating healthcare practice at a flat monthly rate per patient. The practice can seek reimbursement for remote care monitoring and triage services. Most patients pay $0 out-of-pocket due to insurance coverage.
2. Pete – Consumer Hardware and Wellness Subscription: Pete is sold as a consumer device direct-to-consumer via website, with a 2026 ship date. Consumers pay upfront for the device ($1 reservation + full price at launch). HSA/FSA cards accepted. The device targets general wellness users without insurance or prescription requirements.
3. Seed Funding: Starling Medical raised $3.4 million in seed funding led by Rebel Fund with participation from Y Combinator and other investors to develop medical devices, expand the team, and scale remote patient monitoring programs.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Starling Medical develops at-home urine analysis devices that passively capture urine samples via a toilet-mounted spectrophotometer and transmit health data via Bluetooth to a nurse-monitored cloud platform. Its flagship UrinDx device is prescribed by healthcare providers for patients with recurrent UTIs and reimbursed through insurance, while the Pete wellness device is sold direct-to-consumer for hydration tracking.

Differentiator

Problem solved

Functional benefit

Brands

• UrinDx: An at-home urine monitoring device for daily urinary health analysis, designed for patients with recurrent urinary tract infections (rUTIs). Currently pursuing FDA clearance.
• Pete

Products and services

• UrinDx UrinDx is an at-home urine monitoring medical device that becomes part of the bathroom routine, snapping onto a toilet to passively capture urine samples via spectrophotometry. Data is sent nightly via Bluetooth to Starling's care team, which reaches out to schedule appointments if clinical concern is detected. The device is prescribed by healthcare providers (urologists, primary care physicians, OBGYNs) for patients with recurrent UTIs, and the program is covered by insurance with most patients paying $0 copay. Currently pursuing FDA clearance.
• Pete Pete is a consumer wellness urine scanner designed for general hydration and urinary wellness tracking without a prescription. It installs in the toilet and uses a mini-spectrophotometer to capture unlimited daily samples, automatically cleaning via toilet flush and calibrating before each use. The device builds a personalized 'spectral fingerprint' of each user's urine for tracking hydration and clarity, with a 6-month use life and free device replacements. Sold direct-to-consumer via the Starling website with HSA/FSA payment acceptance.

Quantifiable outcome

• 8% of nurse care team calls resulted in confirmed symptoms requiring clinical workflow initiation (June 2023–September 2024), indicating effective pre-symptomatic triage and low false-positive escalation rate.
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• Healthcare Provider Partners (Urologists, Primary Care, OBGYNs)coreStrategic or Co-development PartnerStarling partners with select clinics and physicians to prescribe UrinDx to patients. Providers recommend the program; Starling ships devices, provides StarStream dashboard access, and invoices the practice monthly. The provider relationship is central to the revenue model and clinical workflow.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Everlywell: Direct-to-consumer at-home health testing platform offering a broad menu of diagnostic tests, including UTI screening. Comparable business model and DTC channel for consumer urine/urinary health diagnostics.
• LetsGetChecked: At-home diagnostics platform providing self-collected lab tests including urinary tract infection testing with telehealth follow-up. Direct competitor in the at-home UTI testing and chronic monitoring space.
• Healthy.io: Israel-based digital diagnostics company offering smartphone-camera-based urinalysis (Dip.io) for UTIs, CKD screening, and prenatal care. Competes with Starling in the at-home urine diagnostics category, though via a different capture modality (dipstick + smartphone camera vs. toilet spectrophotometer).
• Scanwell Health: Developed a smartphone-based at-home UTI test (subsequently partnered with BD). Directly competes in the consumer-facing UTI home-diagnostics category with similar clinical/consumer strategy.
• Withings: French consumer health electronics company that launched U-Scan, a toilet-mounted urine analysis cartridge that performs chemical analysis of urine each visit. Most direct comparable on form factor and consumer urine-monitoring concept, though Withings is a larger, established brand.

Broad incumbents

• Dexcom: Established continuous glucose monitoring leader that has expanded into broader metabolic and connected-health monitoring. Provides a benchmark for how a continuous-monitoring hardware + software platform can scale into a category-defining franchise.
• RenalytixAI: Public diagnostics company focused on kidney disease (KidneyIntelX) using AI on blood-based biomarkers. Broader incumbent in renal diagnostics with FDA-authorized tests, contrasting with Starling's pre-clearance home urine platform.
• BioIntellisense: Continuous multi-parameter wearable monitoring platform with FDA-cleared BioSticker and BioButton devices used in hospital-at-home and RPM programs. Competes in remote patient monitoring services where Starling's StarStream operates.
• Current Health (Humana): Enterprise remote patient monitoring platform acquired by Humana, focused on hospital-at-home and chronic-condition monitoring. Competes with Starling's provider-billed RPM model at the platform and service layer.

Emerging players

• Vivoo: Wellness-focused at-home urine analysis strips paired with a smartphone app, with similar hydration/nutrition tracking framing as Pete. Competes in the same consumer wellness urine monitoring category but via dipstick rather than toilet-mounted hardware.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/StarlingMedical
• LinkedInlinkedin.com/company/64570104

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds8 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Starling Medical